Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (Delaware) reports on events occurring on July 10, 2018, specifically the results of the company's annual meeting of stockholders. The registrant is identified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and stockholder voting results rather than financial performance data.
Material Changes and Voting Results
Stockholders approved three key matters at the annual meeting:
- Director Elections: Class I nominees Jessica D. Grossman, M.D., and Susan L. Kelley, M.D., were elected to three-year terms expiring in 2021.
- Jessica D. Grossman: 4,357,441 votes for; 19,006 votes withheld.
- Susan L. Kelley: 4,232,215 votes for; 44,232 votes withheld.
- Stock Incentive Plan: The Amended and Restated 2014 Stock Incentive Plan was approved with 4,109,519 votes for and 96,980 votes against.
- Auditor Ratification: Mayer Hoffman McCann P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018, with 8,629,597 votes for and 52,128 votes against.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. It references a previously filed proxy statement (May 31, 2018) for details regarding the terms of the Amended and Restated 2014 Plan.
Investor Verification Checklist
- Verify the specific terms and share limits of the Amended and Restated 2014 Stock Incentive Plan in the definitive proxy statement filed on May 31, 2018.
- Confirm the total number of shares outstanding to contextualize the voting percentages for director elections and plan approval.
- Review the company's most recent 10-K or 10-Q for financial metrics not included in this 8-K.